developed for medical patients with acute VTE resulted in decreased utilization of hospital resources and healthcare costs, suggesting that further research is warranted in this area.
Conclusion:
The prevention and management of VTE can be optimized by the development and local implementation of standardized evidence-based clinical pathways.
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INTRODUCTION
Pathological blood clots in the venous circulation, generally known as deep vein thromboses (DVT), usually arise via one of three pathogenic processes, sometimes referred to as Virchow's triad [1] : (1) hypercoagulability of the blood, (2) reduced or static blood flow, and (3) vessel damage because of injury or disease [2, 3] . Pulmonary embolism (PE) results when one or more of these abnormal clots break away from the original site and travel to the lungs where they can lead to serious consequences. Together, DVT and PE comprise venous thromboembolism (VTE) [4] .
Approximately 350,000-900,000 patients in the US experience a VTE episode each year, and an estimated 100,000 of these will die because of related complications-sobering statistics which define the significant unmet medical need for this patient population [4] . For patients who experience an initial VTE episode, approximately 50% go on to develop post-thrombotic syndrome, which is characterized by discomfort, discoloration, swelling, and even ulcers in the affected limb in severe cases [4, 5] .
Current treatment guidelines support a number of anticoagulation approaches, and these are dependent on the clinical details of an individual VTE event, the stage of the disease, and any associated co-morbidities. following 5-10 days of initial therapy with a parenteral anticoagulant) [10] , and rivaroxaban (for the treatment of DVT and PE; for the reduction in the risk of recurrent DVT and PE; and for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery) [11] . The role that each of these newer agents will play in the management of VTE will be defined by ongoing clinical trials and real-world experience over the next few years. As a VTE episode progresses, patients will most likely transition through a number of defined clinical settings in advanced healthcare environments [12] . These transitions may include a progression from the emergency room (ER) to the intensive care unit (ICU).
Then, once the acute episode is stable, the patient may be transferred to the ''step-down'' unit before being sent to a general medical-surgical floor, and so forth, until the patient is finally discharged [13] . These physical transitions can parallel the patient's progression through the various stages of a VTE episode including abnormal clotting events and their sequelae, immediate treatment and long-term management, and the potential for readmission because of recurrent VTE [13] .
Therefore, the initial VTE risk assessment performed at first contact with the healthcare system should require re-evaluation after each transition. Any changes noted in the patient's overall VTE risk evaluation resulting from their updated clinical status should call for reconsideration of their ongoing VTE prophylaxis, and any planned long-term regimens [12, 14] .
The objective of this narrative review was to present an overview of the numerous transitions patients experience as they progress through VTE clinical events, and how these transitions can impact their clinical care. 
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CHANGES IN CLINICAL STATUS MAY WARRANT UPDATES TO A PATIENT'S OVERALL RISK FOR VTE
The American College of Chest Physicians' evidence-based clinical practice guidelines for VTE prophylaxis, as well as those from the International Consensus Statement on the prevention and treatment of VTE, are defined by a patient's overall VTE risk and medical status [15] [16] [17] . The relative risk of VTE, including both DVT and/or PE, that may arise during a hospital stay can vary significantly depending on the underlying medical condition of the patient. However, while the number and type of VTE risk factors may generally inform overall risk of VTE, there does not yet exist a clinically validated method to accurately predict specific VTE risk for an individual patient [13] . The general incidence of DVT events in hospitalized patients varies by their medical/surgical service, as shown in Table 1 [13] .
For medical patients in the acute phase of their hospitalization, and who are considered to be at low risk of thrombosis, pharmacologic or mechanical prophylaxis is not recommended [15] . However, if acutely ill medical patients are at increased risk of thrombosis because of immobilization and concurrent risk factors or co-morbidities (e.g., age [40 years, prior history of VTE, serious infection), then thromboprophylaxis with LMWH, low-dose unfractionated heparin (LDUH) two or three times daily, or fondaparinux is recommended [15, 17] . However, it should be noted that extension of thromboprophylaxis beyond the timeframe when the patient is immobilized, or the full course of the acute hospital stay, is not recommended in this patient population [15] .
Prophylaxis with LMWH rather than LDUH is also preferred as it may be administered as a single injection daily, is associated with less hemorrhagic complications and less heparin-induced thrombocytopenia [17] . Recommendations for thromboprophylaxis
for patients who will undergo major orthopedic surgery include the use of one of the following pharmacologic or mechanical approaches:
LMWH; fondaparinux; dabigatran, apixaban, rivaroxaban (for total hip or knee arthroplasty, but not hip fracture surgery); LDUH; adjusted-dose vitamin K antagonist; or an IPCD for a minimum of 10-14 days [16, 17] .
Aspirin, in conjunction with compression devices, can be used for the prophylaxis of VTE in high-risk patients undergoing orthopedic surgery [18] . Note that the oral factor Xa inhibitor anticoagulants, namely apixaban and rivaroxaban, have been FDA approved for DVT prophylaxis following hip or knee replacement surgery. The recommended duration of such prophylaxis is 10-14 days although it can be extended for up to 35 days [16] .
For patients undergoing major orthopedic surgery who are at an increased risk for Critical care patient With no prophylaxis and routine objective screening for DVT DVT deep vein thromboses bleeding, either an IPCD or no prophylaxis is recommended [16] . Inferior vena cava filters are not recommended for primary prevention in patients who have contraindications to both pharmacologic and mechanical thromboprophylaxis [16] . Further, Doppler (or duplex) ultrasonography as a screening tool is not recommended before hospital discharge [16] . Additionally, thromboprophylaxis is not recommended in patients with isolated lower extremity injuries requiring immobilization, or in patients without prior history of VTE who are undergoing knee arthroscopy [16] .
Patients with cancer have a 2-year cumulative incidence of VTE between 0.8% and 8%, depending on the type of malignancy [19, 20] . Since VTE is a major cause of morbidity and mortality in cancer patients, they may benefit from prophylaxis and careful monitoring for changes in their VTE risk levels [20] .
Thromboprophylaxis is generally not recommended for outpatients with cancer who have no additional risk factors for VTE [15] ; however, for some high-risk patients this may be a prudent approach [21] . On the other hand, the majority of patients with cancer who have been admitted to a hospital will require VTE 
TRANSITIONS IN MEDICAL STATUS AND MANAGEMENT
As a patient is diagnosed and treated for a VTE, they can be expected to transition through various stages of care, while concurrently passing through distinct clinical care environments in a formal healthcare setting [24, 25] . For example, patients will likely present to the ER where, depending on the severity of the event, they may be admitted to the ICU to receive aggressive medical intervention and nursing care. When their clinical status improves, patients may proceed as medically necessary to the ''next'' hospital unit. Upon discharge from the hospital, they will need appropriate follow-up and care, including ongoing anticoagulation therapy appropriate for their underlying condition.
In parallel, patients can also transition through stages of care as their disease progresses from an acute event to initial treatment and response and on through what may become a chronic condition. Upon possible readmission, patients re-enter the healthcare system with a more extensive medical history, which will need to be considered as ''next-step'' treatment options are considered. If re-admitted to the same facility, then continuity of care should be straightforward. If admitted to another facility, however, they will most likely require additional, sometimes duplicative, workup before appropriate treatment decisions can be made. 
CLINICAL PATHWAYS OF ACUTE VTE
Acute VTE is a prevalent and potentially deadly condition, especially when it is undiagnosed or undertreated. Furthermore, if a VTE episode Table 2 continued Evidence-based protocols for diagnosing and managing this complex condition are continuously being developed [4] . One general strategy to optimize care for the prevention and management of VTE would be to develop a protocol based on a reiterative process that is defined by a number of quality Fig. 1 Sequence and relationships of steps in a quality improvement project aimed at reducing the incidence of hospital-acquired venous thromboembolism [13] . a A VTE protocol offers decision support for risk stratification and a menu of appropriate prophylaxis options for each level of risk. VTE venous thromboembolism, QI quality improvement control steps, and progressive self-assessments to monitor the effectiveness of the evolving pathway (Fig. 1) .
Key steps in this process would include the identification of existing protocols and current practices, and how ''next step'' clinical decisions are made and implemented for individual patients depending on their medical status [13] . Hospital admission outcomes, length of stay, and reutilization were stratified by payer source in study patients (n = 241) and historical data (n = 234) ( 
